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The aim of this study was to investigate the effect of melatonin on oxidative stress and senescence marker protein-30
(SMP30) as well as osteopontin (OPN) expression in the hippocampus of rats subjected to vascular dementia (VD). A
total of 72 male rats were divided into six groups (n= 12 each) as follows: (i) untreated control (CON), (ii) sham-
operated group, (iii) sham-operated+melatonin, (iv) rats exposed to VD induced by permanent bilateral occlusion
of the common carotid arteries (BCCAO) leading to chronic cerebral hypoperfusion, (v) rats exposed to VD+
melatonin, and (vi) rats exposed to VD+ donepezil (DON). At the end of experiment, the hippocampal levels of
acetylcholine (ACh), norepinephrine (NE), and dopamine (Dop) were measured. Expression of OPN was determined
using immunohistochemistry, and SMP30 expression was determined using real-time PCR in the hippocampus.
Hippocampal thiobarbituric acid reactive substances (TBARS) and total antioxidant capacity (TAC) were evaluated.
The BCCAO group showed signiﬁcantly decreased TAC ( p< 0.05) and signiﬁcantly increased in TBARS levels
compared with the CON group. In addition, BCCAO signiﬁcantly decreased ( p< 0.05) the expression of both OPN
and SMP30 and the levels of ACh, NE, and Dop in the hippocampus compared with CON treatment. Treatment with
melatonin signiﬁcantly increased OPN and SMP30 expression and ACh, NE, and Dop levels in the hippocampus
with amelioration of the oxidative stress compared with BCCAO rats. Melatonin might produce a neuroprotective
effect through its antioxidant action and by increasing the expression of SMP30 and OPN that is not comparable with
that of DON.
Keywords: vascular dementia, osteopontin, senescence marker protein-30, melatonin, oxidative stress
Introduction
Chronic cerebral hypoperfusion (CHP) due to cerebrovascular disease (29) is usually
associated with loss of cognitive ability, including memory, language, attention, and
problem-solving ability, which makes it a serious medical, social, and economic burden
for the society (4). Risk factors include hypertension, diabetes, generalized atherosclerosis,
smoking, and heart diseases (29).
Melatonin (N-acetyl-5-methoxytryptamine) is a key endogenous indoleamine secreted
by the pineal gland and other extrapineal tissues such as the retina. Aside from its critical role
in regulating circadian rhythms, melatonin and its metabolites possess well-known
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antioxidant, anti-inﬂammatory, and antiapoptotic properties in the central nervous system
(CNS) (11, 25, 26, 34, 56). These characteristics and the ability of melatonin to quickly and
easily cross the blood–brain barrier made exogenous melatonin administration a drug of
choice against aging (13) and some CNS conditions, such as Parkinson’s disease (38),
ischemia, and stroke (33, 35). To a large extent, these neuroprotective effects of melatonin are
ascribed to its antioxidant and antiapoptotic functions and its role in protecting against
mitochondrial dysfunction (26, 52, 56).
Senescence marker protein-30 (SMP30) was ﬁrst isolated as a hepatocyte aging factor in
1992. The expression of SMP30 was shown to decline with age. It is present in a variety of
tissues, such as the brain, testes, and renal proximal tubular epithelial cells (19). The reported
functions and activities of SMP30 are varied. Its major function is regulating cellular
apoptosis through Ca2+ homeostasis (19, 41). SMP30 exerted antiapoptotic effects through
either sustained and elevated cellular Ca2+ or Fas-mediated apoptosis (19). Moreover,
SMP30-deﬁcient brains showed increased Mac-1 protein and myeloperoxidase activity,
suggesting a putative antioxidant action for SMP30 (46).
Various factors, such as Bcl-2, Bax, cytochrome c, p53, and Fas, have been linked to
apoptosis pathways (12). Bcl-2 was ﬁrst discovered in mammals as an antiapoptosis marker.
If Bcl-2 levels are higher than those of Bax, the condition facilitates cell survival. On the other
hand, when Bax is upregulated compared with Bcl-2, the dimer facilitates apoptosis and
triggers caspase-3 to cause a breakdown of cytoskeletal and nuclear proteins and nucleosomal
fragmentation (22). Thus, the proportion of Bcl-2 relative to Bax may be a key controller of
apoptosis.
Osteopontin (OPN) is a phosphorylated sialic acid-rich non-collagenous bone matrix
protein that is distributed in various body ﬂuids (18). OPN was shown to be an important factor
in bone remodeling. It is also expressed in immune cells including macrophages, neutrophils,
and dendritic cells with varying kinetics. Recent studies have shown that OPN is neuropro-
tective because of its role in downregulating iNOS (27, 28, 49). This decreases reactive oxygen
species (ROS) generation and leads to an antiapoptotic effect by inhibiting mitochondria-
related apoptosis pathways involving cytochrome c, cleaved caspase-3, and Bax (10).
Despite the protective effect of melatonin against oxidative stress and apoptosis induced
by various neurological disorders including stroke and Alzheimer’s disease (AD), the effect
of melatonin on SMP30 and OPN expressions in an animal model of vascular dementia (VD)
has not been investigated. This study was designed to investigate the protective effect of
exogenous melatonin on the expression of SMP30 and OPN, apoptosis, as well as oxidative
stress parameters in a rat model of VD. Preliminary results of this study were presented in an
abstract form by Ismaeel Bin-Jaliah, as a recipient of the Physiological Society Travel Grant,
at the 2017 Festival of Neuroscience that was hosted in April 2017 by the British
Neuroscience Association in Birmingham, England, UK.
Material and Methods
Animals
This study used 72 male Sprague–Dawley rats weighing 170–200 g. All rats were bred and
housed in the research center at the Mansoura University College of Medicine (Mansoura,
Egypt) at a temperature of 23± 1 °C and a 12-h light–dark cycle. All rats had free access to
water. They were fed standard laboratory chow during the acclimatization period before being
divided into groups. All experimental procedures were approved by the medical research
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ethical committee at Mansoura University. The rats were taken care for in accordance with the
Guide for the Care and Use of Laboratory Animals (1996, published by National Academy
Press, 2101 Constitution Ave. NW,Washington, DC 20055, USA) (NIH publication no. 85-23,
revised 1996). This work is part of the collaboration between the Department of Physiology,
College of Medicine, King Khalid University, Abha, Saudi Arabia and the Department of
Medical Physiology, College of Medicine, Mansoura University, Egypt.
Experimental groups and preparation of melatonin. Melatonin (Sigma, St Louis, USA) was
prepared fresh every day 10 min before administration by dissolving 1.72 mg of the drug in
0.5 ml of 96% ethanol to prepare a stock solution. The working solution administered to rats
was prepared by diluting 288 μl of stock solution in 500 ml drinking water to give a ﬁnal
melatonin concentration of 20 μg/ml (42). Seventy-two rats were divided into six
groups (n= 12 each) as follows: (i) untreated control (CON), (ii) sham-operated group,
(iii) sham-operated +melatonin, (iv) exposed to VD based on permanent bilateral occlusion
of the common carotid arteries (BCCAO) leading to CHP was used, (v) exposed to
VD+melatonin (BCCAO +melatonin), and (vi) exposed to VD+ donepezil (BCCAO +
DON). Melatonin was administered orally during the dark period using water bottles covered
with aluminum foil. Melatonin administration started 1 h before induction of 2 vessel
occlusion (2-VO) and continued for 28 consecutive days (36). Equal volumes of drinking
water were supplied to all groups. To daily calculate melatonin consumption, the melatonin-
administered groups were housed at one rat/cage, and daily water consumption was
calculated. Based on this information and based on the rat’s body weight, the average daily
melatonin intake was 187.6 ± 8.62 μg/100 g bwt. DON was administered intraperitoneally (i.
p.) at 3 mg/kg/day for 28 consecutive days.
Global cerebral hypoperfusion (BCCAO). Permanent BCCAO with hypotension (2-VO) was
used to induce CHP (43, 48).
Hippocampi collection. All rats were killed by cervical dislocation after being anesthetized
with sodium pentobarbital (60–70 mg/kg, i.p.). Their brains were removed and immediately
placed into an ice–cold dish. The hippocampus from each brain was quickly dissected
according to the neuroanatomy atlas under a stereomicroscope. The hippocampus was weighed
(average weight: 160± 12.3 mg), frozen in liquid nitrogen, and stored at −80 °C for later use.
Assay of neurotransmitters, TBARS, GSH, CAT, SOD, and TAC. Hippocampus samples were
transferred into a Petri dish and homogenized separately in 0.1 mol Tris-HCl buffer, pH 7.4,
using a Potter-Elvehjem homogenizer (NW Kennesaw, GA 30144, USA) at 4 °C with a
diluting factor of 4. The crude tissue homogenate was centrifuged at a speed of 9,000 rpm for
15 min in a cold centrifuge. The supernatant was collected and stored at −20 °C until the levels
of dopamine (Dop), norepinephrine (NE), and acetylcholine (ACh) concentrations were
measured by ELISA obtained from Abnova (Taipei City 114, Taiwan). Malondialdehyde
was also measured using the thiobarbituric acid reactive substances (TBARS) method (53).
Moreover, total antioxidant capacity (TAC) was measured according to a published method
(20). The results are expressed as trolox equivalents per gram wet tissue weight. The levels of
glutathione (GSH) (Cayman Chemical, Ann Arbor, MI, USA), superoxide dismutase (SOD)
(Cayman Chemical, Ann Arbor), and catalase (CAT) (Northwest Life Science Specialties,
Vancouver, WA, USA) were measured according to the manufacturer’s instructions.
Immunohistochemical localization of OPN in the hippocampus. The right hippocampi of six
rats from the different groups were parafﬁn embedded and cut into 5-μm thick sections on a
microtome. Immunohistochemistry was performed using the avidin–biotin complex (ABC)
technique. First, sections were deparafﬁnized in xylene, dehydrated in a descending ethanol
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series (100%, 90%, and 70%, v/v), immersed in a retrieval solution (DAKO 51700; DAKO
Diagnostics S.A., Barcelona, Spain), and washed in phosphate-buffered solution (PBS) for
5 min. Next, the endogenous peroxidase activity was inhibited with 3% H2O2 in absolute
methanol for 30 min and washed in PBS. Non-speciﬁc antibody binding was blocked by
incubating with normal goat serum (DAKO X 909; DAKO Diagnostics S.A.) in PBS diluted
with the ratio of 1:4. The excess serum was blotted, and the sections were incubated with
primary antibodies (rabbit anti-OPN afﬁnity-puriﬁed polyclonal antibody) diluted with the
ratio of 1:100 in PBS for 2 h at room temperature. Sections were washed thrice for 5 min in
PBS. The sections were incubated for 30 min in pre-diluted anti-rabbit biotinylated universal
secondary antibody. At the end of 30 min, sections were washed in PBS for 5 min and
incubated in prepared ABC reagent for another 30 min (DAKO LSAB 2 Kit; DAKO
Diagnostics S.A.). Peroxidase detection was achieved using 3,30-diaminobenzidine tetra-
hydrochloride as a chromogen followed by washing in PBS for 5 min. PBS was used in place
of the antibody as a negative CON. Positive immunoreactions were characterized by brown
dot-like cytoplasmic expression, whereas negative immunoreactivity remained unlabeled.
The density of the antibody labeling was measured using an image analyzer (SAMBA 2005;
Villeneuve d’Ascq, France). The density values were expressed as percentages [optical
density = log10 (1/light transmission)]. This densitometric analysis has previously been used
as a semiquantitative technique in rats (44).
Quantitative real-time PCR (Q-PCR) for determining the levels of gene expression. Total
RNA isolation, puriﬁcation, and concentration measurement were performed as described by
Sakr et al. (41). The sequences of the primers used were designed by other authors: SMP30,
forward: 5′AGGCATCAAAGTGTCTGCTGTTT3′; reverse: 5′GACTGTCGAAGTGCCA
CTGAACT3′ (17). Bax, forward: 5′CCAGGACGCATCCACCAAGAAGC3′; reverse: 5′
TGCCACACGGAAGAAGACCTCTCG3′ (136-bp product size) (23). Bcl-2, forward: 5′
GGATGACTTCTCTCGTCGCTACCGT3′; reverse: 5′ATCCCTGAAGAGTTCCTCCAC
CAC3′ (118-bp product size) (23). β-actin, forward: 5′GTCGTACCACTGGCATTGTG3′;
reverse: 5′CTCTCAGCTGTGGTGGTGAA3′ (51).
Reactions were performed in duplicates as discussed previously (3). For Bax and Bcl-2,
Q-PCR was performed according to the method described by Li et al. (23) using the following
mix and program: the reactions were performed in a 20-μl volume mix containing 10-μl
SYBR Green I mixture, 1-μl primers, 1-μl cDNA, and 1-μl sterile, and distilled deionized
water. Cycling conditions were as follows: 3 min at 95 °C, 44 cycles of 15 s at 95 °C, 20 s at
60 °C, and 15 s at 72 °C.
The speciﬁc ampliﬁcation of each product was performed as previously described (3).
The relative gene expression levels were calculated using arithmetic formulae. The CON non-
treated samples were used as calibrators. The amount of target, normalized to an endogenous
housekeeping gene (β-actin) and relative to the calibrator, is given by ΔΔCT, where
ΔΔCT=ΔCT (sample)−ΔCT (calibrator), and ΔCT is the CT of the target gene subtracted
from the CT of the housekeeping gene. For the untreated CON sample, ΔΔCT equals zero,
and 20 equals one, so that the fold change in gene expression relative to the untreated CON
equals one. For the treated samples (studied group samples), evaluation of ΔΔCT indicates
the fold change in gene expression relative to the untreated CON.
Statistical analysis
The data were expressed as the mean± standard deviation. Data were processed and analyzed
using the SPSS version 10.0 (SPSS Inc., Chicago, IL, USA). One-way analysis of variance
Melatonin and dementia 41
Physiology International (Acta Physiologica Hungarica) 105, 2018
was carried out, followed by Tukey’s post-hoc test. Pearson’s correlation statistical analysis
was performed to detect a probable signiﬁcance between two different parameters. The
results were considered signiﬁcant, if p≤ 0.05.
Results
Compared with the CON group, the sham and sham +melatonin groups did not exhibit any
signiﬁcant changes in any of the measured parameters (data not shown).
Effect of melatonin treatment after BCCAO on the hippocampal levels of TBARS, GSH, CAT,
SOD, and TAC
As expected, BCCAO produced a signiﬁcant (p< 0.05) increase in TBARS. It also
signiﬁcantly decreased the TAC, SOD, CAT, and GSH (p< 0.05) compared with the CON
group. In rats that received melatonin, TBARS signiﬁcantly decreased (p< 0.05) with
signiﬁcantly increased SOD, CAT, GSH, and TAC (p< 0.05) compared with BCCAO in the
hippocampus. Although melatonin changed TBARS, TAC, SOD, CAT, and GSH, the results
were still signiﬁcant compared with the CON group. DON treatment after BCCAO did not
signiﬁcantly change the oxidative stress parameters compared with the BCCAO and
BCCAO+melatonin groups (Figs 1 and 2).
Effect of melatonin treatment on the hippocampal levels of ACh, NE, and Dop after BCCAO
In response to BCCAO, the levels of ACh, NE, and Dop signiﬁcantly dropped ( p< 0.05) in
the hippocampus compared with the CON group. Melatonin treatment after BCCAO
signiﬁcantly (p< 0.05) increased the levels of ACh, NE, and Dop compared with the
BCCAO group, but it was still signiﬁcantly ( p< 0.05) lower than in the CON group.
Moreover, DON treatment plus BCCAO signiﬁcantly ( p< 0.05) increased the hippocampal
levels of ACh, NE, and Dop compared with the BCCAO group. However, it was still
Fig. 1. The level of TBARS (A) and TAC (B) in the hippocampus. All data are expressed as the mean± SD (n= 12).
CON: control group; BCCAO: bilateral common carotid artery occlusion; DON: donepezil; TBARS: thiobarbituric
acid reactive substances; TAC: total antioxidant capacity. a: p< 0.05 compared with the control group. b: p< 0.05
compared with the BCCAO non-treated group. c: p< 0.05 compared with the BCCAO+melatonin-treated group
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Fig. 2. The hippocampal levels of GSH (A), SOD
(B), and CAT (C) hippocampus in all groups. All
data are expressed as the mean± SD (n= 12).
a: p< 0.05 compared with the control group.
b: p< 0.05 compared with the BCCAO non-treated
group. c: p< 0.05 compared with the BCCAO+
melatonin-treated group
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signiﬁcantly (p< 0.05) lower than in the CON group. DON treatment after BCCAO
produced an insigniﬁcant ( p> 0.05) increased ACh compared with the BCCAO +melatonin
group. On the other hand, melatonin signiﬁcantly ( p< 0.05) increased the hippocampal
levels of both NE and Dop compared with the DON group (Fig. 3).
Effect of melatonin treatment on the expression of SMP30, Bax, and Bcl-2 in the rat
hippocampus
Compared with CON rats, SMP30 and Bcl-2 signiﬁcantly decreased (p< 0.05) with a
signiﬁcant increase (p< 0.05) in Bax in response to BCCAO and BCCAO +DON (Fig. 4).
Melatonin increased the expression of SMP30 and Bcl-2 and downregulated Bax signiﬁ-
cantly (p< 0.05) compared with BCCAO. Melatonin signiﬁcantly ( p< 0.05) restored
SMP30, Bcl-2, and Bax expression to levels comparable with CON. BCCAO +DON
produced less ameliorative effects compared with melatonin.
Effect of melatonin treatment on the expression of OPN in the rat hippocampus
In response to BCCAO, the expression of OPN signiﬁcantly decreased ( p> 0.05) compared
with that in CON rats (Figs 5 and 6). Melatonin after BCCAO signiﬁcantly increased
( p< 0.05) the OPN expression compared with the BCCAO group, but it was still signiﬁ-
cantly lower (p< 0.05) than that in the CON group.
Correlations
Figure 7A showed a negative Pearson’s correlation between TBARS and SMP30
(r=−0.8095) ( p< 0.0001) for all rats (n= 48). Figure 7B showed a negative Pearson’s
correlation between TBARS and OPN (r=−0.9396) (p< 0.0001) for all rats (n= 48).
Discussion
This study was performed with BCCAO to study the effect of melatonin on VD in rats. VD is
associated with: (i) decreased ACh, NE, and Dop; (ii) increased oxidative stress parameters
with decreased antioxidant enzymes; (iii) increased apoptosis marked by decreased Bcl-2 and
increased Bax; and (iv) decreased expression of both OPN and SMP30. Treatment with the
neurohormone melatonin for 28 days in a rat model of VD ameliorated oxidative stress,
increased antioxidant enzymes and capacity, and upregulated the suppressed expression of
OPN and SMP30. In addition, the antiapoptosis gene Bcl-2 increased with decreased Bax
expression in the hippocampus.
Hippocampi isolated from BCCAO rats showed a signiﬁcant decrease in the level of
the neurotransmitters compared with the CON group. These results were consistent with
previous studies (43). On the other hand, melatonin increased the level of neurotransmit-
ters. These data agreed with previous studies that examined the effects of melatonin on
various rat models of neurotoxicity. The mechanism by which melatonin increased ACh is
dependent upon the prevention of peroxynitrite-induced inhibition of choline transport and
choline acetyl transferase activity in several neuronal proteins from synaptosomes (24) and
inhibition of NE and Dop reuptake (7). In this study, we used DON at 3 mg/kg/day i.p. as
described by Birks and Harvey (5). They concluded that it improves cognition in dementia.
In addition, Sakr et al. (43) conﬁrmed that DON improved the working and reference
memories in a rat model of VD (43). DON is one of the three ACh esterase inhibitors
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Fig. 3. The level of acetylcholine (A),
norepinephrine (B), and dopamine (C) (ng/mg
tissue) in the hippocampus. All data are
expressed as the mean± SD (n= 12).
a: p< 0.05 compared with the control group.
b: p< 0.05 compared with the BCCAO non-
treated group. c: p< 0.05 compared with the
BCCAO+melatonin-treated group
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Fig. 4. (A) SMP30, (B) Bcl-2, and (C) Bax
expression in the hippocampus of all groups.
All data are expressed as the mean± SD
(n= 12). a: p< 0.05 compared with the control
group. b: p< 0.05 compared with the BCCAO
non-treated group. c: p< 0.05 compared with
the BCCAO+melatonin-treated group
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currently approved for treating AD symptoms and delaying the decline in cognitive
function (32).
It is well known that ischemic hypoxia is associated with decreased neuronal activity,
neurotransmitter synthesis, and uptake (47). BCCAO increased oxidative stress in the
Fig. 5. Osteopontin immunoreactivity (arrows) appears as brown pigment. (A) Control group, (B) untreated BCCAO
group, (C) BCCA+melatonin, (D) BCCAO+DON
Fig. 6. Densitometric analysis of the
immunohistochemical labeling of osteopontin
(OPN) protein in the hippocampus tissues of all
groups of rats. Values are given as themean± SD
of ﬁve areas/slide of six rats in each group. OD:
optical density. a: p< 0.05 compared with the
control group. b: p< 0.05 compared with the
BCCAO non-treated group. c: p< 0.05 compared
with the BCCAO+melatonin-treated group
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hippocampus compared with CON rats. Our results showed that chronic ischemia increased
the hippocampus TBARS and decreased GSH, CAT, and SOD compared with CON rats due
to excessive ROS generation that might induce functional and structural damage of neuronal
cells (8, 9, 31). The lack of nutrients led to a state of disturbed cellular homeostasis that ended
in cell death (54). Neuronal ischemia is associated with stagnant hypoxia and a decreased
partial pressure of oxygen that causes a reduction in available cellular O2, which is the
ultimate electron acceptor in the electron transport chain with excessive generation of
superoxide anion (O2
−). In turn, hydrogen peroxide (H2O2) and hydroxyl radicals (OH
−)
are formed. The hypoxia-induced generation of ROS can cause protein oxidation, DNA and
RNA oxidation, lipid peroxidation, and neuronal dysfunction or death (6). The brain is
sensitive to oxidative stress due to (i) an abundance of polyunsaturated fatty acids, (ii)
deﬁcient antioxidant defence, (iii) a high rate of O2 utilization, and (iv) a high content of
transition metals, such as copper and iron, in several regions (37). Furthermore, the
antioxidant and anti-inﬂammatory effects of melatonin cause a reduction in the production
of ROS and reduced protection against mitochondrial dysfunction (11, 26, 52, 56). Our data
showed that melatonin decreased TBARS and increased SOD, CAT, GSH, and TAC.
Receptor-independent actions of melatonin and its metabolites relate to the ability to directly
quench free radicals and non-radical toxic species. Excessive free-radical generation is
notoriously destructive and kills cells secondary to massive oxidative damage. This induces
cellular apoptosis or necrosis. These results agreed with previous reports (54). Recently, Ali
et al. (1) showed that melatonin could produce an antioxidant effect and could modulate the
RAGE/NF-KB/JNK signaling pathway in a mouse model of aging. In addition, this study
showed that melatonin modulated the ratio between Bcl-2 and Bax to inhibit apoptosis. These
results agreed with previous studies (2, 14, 34).
SMP30 acts as an anti-aging agent through a Ca2+ regulator, antioxidants, and
gluconolactonase, which is a key enzyme in ascorbic acid (vitamin C) biosynthesis
(30). It exerts its antioxidant effect without affecting the major antioxidant enzymes,
SOD, CAT, and reduced GSH peroxidase in the brain (46). In response to cerebral
ischemia, the expression of SMP30 and Bcl-2 signiﬁcantly decreased with increased Bax
compared with CON rats. These results suggested that hypoxia and ischemia led to the
apoptotic and aging processes of the neuronal tissues through acceleration and facilitation
of oxidative stress. Those ﬁndings are in agreement with previous studies (45). Instead,
Fig. 7. (A) shows a negative correlation between TBARS and OPN (r=−0.9396) ( p< 0.0001) for all rats (n= 48).
(B) shows a negative correlation between TBARS and SMP30 (r=−0.8095) ( p< 0.0001) for all rats (n= 48)
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melatonin treatment after BCCAO upregulated the downregulated expression of SMP30
compared with the BCCAO group. Melatonin exerted its anti-aging effect by upregulating
multiple genes. Epigenetic actions of melatonin that relate to brain aging, and neurode-
generative diseases remain poorly characterized. However, chronic treatment with melato-
nin in the SAMP8 model could reduce oxidative stress and neurodegenerative pathways, as
well as tau phosphorylation and markers of cerebral aging and neurodegeneration, in
SAMP8 brains. This indicated the neuroprotective and anti-aging effect of melatonin (15).
Recently, Yun et al. (55) showed that melatonin restored the expression of SMP30, which is
normally suppressed by p-cresol in chronic kidney failure patients due to induction of the
autophagy pathway. Their ﬁndings suggested that the administration of melatonin could
rescue renal function in patients with chronic kidney failure (55).
Agreeing with our results, a previous study demonstrated that spinal cord ischemia
could depress the expression of OPN (40). Several studies advocate that OPN might be
involved in the cellular response to ischemic injury. Its effects in ischemia have been
difﬁcult to ascertain. OPN has actions that are both pro-inﬂammatory and anti-inﬂamma-
tory (27). Previous studies on nervous tissues have shown that the OPN mRNA is expressed
in rat’s CNS neurons, and it is upregulated in microglia in response to brain (21) and spinal
cord injury (16). In response to melatonin treatment, OPN signiﬁcantly increased compared
with BCCAO. Previous reports that concur with our data concluded that melatonin
increased OPN expression and synthesis (39, 50). OPN increased to exert its neuropro-
tective effects against tissue hypoxia and ischemia by decreasing the induction of nitric
oxide synthase, increasing NF-kB activity and increasing PI3K activation (28). In addition,
the upregulation of OPN aids in inhibiting cleaved caspase-3 (10). OPN is inversely
correlated with TBARS in these data.
These ﬁndings could suggest that melatonin exerted anti-aging and antioxidant effects
by upregulating the downregulated SMP30 and OPN. Therefore, treating with natural
antioxidants and free-radical scavengers such as melatonin is a possible therapeutic strategy
for ameliorating oxidative stress and brain injury resulting from CHP. Further research on
these molecules is required to explore their potential and conﬁrm their candidature as
neuroprotective drugs.
One of the limitations of this study was the separation of melatonin-treated rats. They
were housed separately, whereas all other rats were housed in groups. Isolation might alter
several physiological functions, and melatonin may modify these physiological functions.
Conclusions
CHP increased oxidative stress and reduced expression of the antiapoptotic OPN and the anti-
aging SMP30. Post-ischemic treatment with melatonin could exert neuroprotective effects by
upregulating the suppressed anti-aging genes, antiapoptotic genes, and antioxidant enzymes.
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